Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer

A study presented at the 2020 ASCO Scientific Program combining mirvetuximab soravtansine with bevacizumab to treat platinum-agnostic ovarian cancer demonstrated an encouraging overall response rate and tolerability profile regardless of platinum status.

Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news